Regulus Therapeutics, Inc.

( )
RGLS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
SAVACassava Sciences, Inc. -6.90%49.690.0%$331.13m
VRXValeant Pharmaceuticals International, Inc. 0.25%28.5014.1%$167.70m
PRGOPerrigo Co. Plc -1.63%44.736.9%$131.09m
HZNPHorizon Therapeutics Plc -0.80%112.085.5%$127.22m
ICLRICON plc -0.01%275.042.8%$123.32m
CTLTCatalent, Inc. -0.03%128.902.0%$115.63m
JAZZJazz Pharmaceuticals Plc 2.54%140.702.1%$100.37m
UTHRUnited Therapeutics Corp. -0.28%187.0714.0%$64.01m
ARGXargenx SE -0.48%293.740.0%$52.27m
BHCBausch Health Cos., Inc. 0.25%28.500.0%$46.49m
AXSMAxsome Therapeutics, Inc. -1.28%40.101.8%$41.54m
GRVIGrove, Inc. -8.31%6.400.0%$36.76m
PCRXPacira Biosciences, Inc. -1.19%53.209.8%$32.21m
ENDPEndo International Plc 0.73%4.178.5%$31.75m
INDPIndaptus Therapeutics, Inc. -0.51%7.800.0%$27.93m

Company Profile

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded on September 5, 2007 and is headquartered in San Diego, CA.